Patents by Inventor Paul J. BRETT

Paul J. BRETT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic conjugates and methods of use thereof
    Patent number: 11235046
    Abstract: Disclosed are capsular polysaccharide (CPS)-protein immunogenic conjugates useful for providing protection against any condition or disease associated with Burkholderia pseudomallei or Burkholderia mallei, such as melioidosis or glanders, respectively. For example, a disclosed CPS-protein immunogenic conjugate includes purified 6-deoxyheptan capsular polysaccharide (CPS) from B. pseudomallei chemically activated and covalently linked to recombinant CRM 197 diphtheria toxin mutant (CRM197) to produce CPS-CRM197. Methods of inducing an immune response are disclosed. The methods include the use of a CPS-protein immunogenic conjugate, alone or in conjunction with other agents, such as Hcp1 and TssM, to prevent infection with B. pseudomallei or B. mallei. Also disclosed are methods for treating a subject having melioidosis or glanders.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 1, 2022
    Assignee: Nevada Research & Innovation Corporation
    Inventors: Paul J. Brett, Mary N. Burtnick
  • IMMUNOGENIC CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20200338179
    Abstract: Disclosed are capsular polysaccharide (CPS)-protein immunogenic conjugates useful for providing protection against any condition or disease associated with Burkholderia pseudomallei or Burkholderia mallei, such as melioidosis or glanders, respectively. For example, a disclosed CPS-protein immunogenic conjugate includes purified 6-deoxyheptan capsular polysaccharide (CPS) from B. pseudomallei chemically activated and covalently linked to recombinant CRM 197 diphtheria toxin mutant (CRM197) to produce CPS-CRM197. Methods of inducing an immune response are disclosed. The methods include the use of a CPS-protein immunogenic conjugate, alone or in conjunction with other agents, such as Hcp1 and TssM, to prevent infection with B. pseudomallei or B. mallei. Also disclosed are methods for treating a subject having melioidosis or glanders.
    Type: Application
    Filed: November 2, 2018
    Publication date: October 29, 2020
    Applicant: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA REN
    Inventors: Paul J. BRETT, Mary N. BURTNICK